These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39361282)

  • 1. Time to COVID-19 Vaccination by Language and Country of Origin.
    Nolan MB; Chrenka E; DeSilva MB
    JAMA Netw Open; 2024 Oct; 7(10):e2437388. PubMed ID: 39361282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines.
    Kelly JD; Leonard S; Hoggatt KJ; Boscardin WJ; Lum EN; Moss-Vazquez TA; Andino R; Wong JK; Byers A; Bravata DM; Tien PC; Keyhani S
    JAMA; 2022 Oct; 328(14):1427-1437. PubMed ID: 36156706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rates of and Factors Associated With Primary and Booster COVID-19 Vaccine Receipt by US Veterans, December 2020 to June 2022.
    Bajema KL; Rowneki M; Berry K; Bohnert A; Bowling CB; Boyko EJ; Iwashyna TJ; Maciejewski ML; O'Hare AM; Osborne TF; Viglianti EM; Hynes DM; Ioannou GN
    JAMA Netw Open; 2023 Feb; 6(2):e2254387. PubMed ID: 36729454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 vaccine uptake among non-US-born populations in the United States, 2020-2022.
    Nolan MB; Chrenka E; Walker P; Steiner A; Rodrigues KK; Michel JJ; Yun K; Payton C; Young J; Mamo B; Frumholtz M; DeSilva M
    Vaccine; 2024 Apr; 42(12):3115-3121. PubMed ID: 38604910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 Vaccination Coverage and Factors Associated With Vaccine Uptake Among People With HIV.
    Hechter RC; Qian L; Liu IA; Sy LS; Ryan DS; Xu S; Williams JTB; Klein NP; Kaiser RM; Liles EG; Glanz JM; Jackson LA; Sundaram ME; Weintraub ES; Tseng HF
    JAMA Netw Open; 2024 Jun; 7(6):e2415220. PubMed ID: 38842808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study.
    Arbel R; Peretz A; Sergienko R; Friger M; Beckenstein T; Duskin-Bitan H; Yaron S; Hammerman A; Bilenko N; Netzer D
    Lancet Infect Dis; 2023 Aug; 23(8):914-921. PubMed ID: 37062302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 vaccination during pregnancy: coverage and safety.
    Blakeway H; Prasad S; Kalafat E; Heath PT; Ladhani SN; Le Doare K; Magee LA; O'Brien P; Rezvani A; von Dadelszen P; Khalil A
    Am J Obstet Gynecol; 2022 Feb; 226(2):236.e1-236.e14. PubMed ID: 34389291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Preferred Language and Timing of COVID-19 Vaccine Uptake and Disease Outcomes.
    Quadri NS; Knowlton G; Vazquez Benitez G; Ehresmann KR; LaFrance AB; DeFor TA; Smith MK; Mann EM; Alpern JD; Stauffer WM
    JAMA Netw Open; 2023 Apr; 6(4):e237877. PubMed ID: 37043199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disparities in COVID-19 vaccination receipt by race, ethnicity, and social determinants of health among a large patient population in a network of community-based healthcare centers.
    Groom HC; Biel FM; Crane B; Sun E; Georgescu JP; Weintraub ES; McNeil MM; Jazwa A; Smith N; Owens-Jasey C; Naleway AL; Schmidt T
    Vaccine; 2024 Oct; 42(24):126288. PubMed ID: 39241356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years.
    Feldstein LR; Britton A; Grant L; Wiegand R; Ruffin J; Babu TM; Briggs Hagen M; Burgess JL; Caban-Martinez AJ; Chu HY; Ellingson KD; Englund JA; Hegmann KT; Jeddy Z; Lauring AS; Lutrick K; Martin ET; Mathenge C; Meece J; Midgley CM; Monto AS; Newes-Adeyi G; Odame-Bamfo L; Olsho LEW; Phillips AL; Rai RP; Saydah S; Smith N; Steinhardt L; Tyner H; Vandermeer M; Vaughan M; Yoon SK; Gaglani M; Naleway AL
    JAMA; 2024 Feb; 331(5):408-416. PubMed ID: 38319331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
    Dixit A; Bennett R; Ali K; Griffin C; Clifford RA; Turner M; Poston R; Hautzinger K; Yeakey A; Girard B; Zhou W; Deng W; Zhou H; Schnyder Ghamloush S; Kuter BJ; Slobod K; Miller JM; Priddy F; Das R;
    Lancet Infect Dis; 2024 Jul; 24(7):687-697. PubMed ID: 38518789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health System.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Xie F; Ackerson BK; Takhar H; Ogun OA; Simmons S; Zamparo JM; Tseng HF; Jodar L; McLaughlin JM
    JAMA Netw Open; 2023 Jan; 6(1):e2251833. PubMed ID: 36662525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for COVID-19 hospitalisation after booster vaccination during the Omicron period: A French nationwide cohort study.
    Turpin A; Semenzato L; Le Vu S; Jabagi MJ; Bouillon K; Drouin J; Bertrand M; Kanagaratnam L; Weill A; Dray-Spira R; Zureik M; Botton J
    J Infect Public Health; 2024 Jul; 17(7):102450. PubMed ID: 38823086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 Bivalent Booster Vaccination Coverage and Intent to Receive Booster Vaccination Among Adolescents and Adults - United States, November-December 2022.
    Lu PJ; Zhou T; Santibanez TA; Jain A; Black CL; Srivastav A; Hung MC; Kriss JL; Schorpp S; Yankey D; Sterrett N; Fast HE; Razzaghi H; Elam-Evans LD; Singleton JA
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(7):190-198. PubMed ID: 36795677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Hardt K; Vandebosch A; Sadoff J; Le Gars M; Truyers C; Lowson D; Van Dromme I; Vingerhoets J; Kamphuis T; Scheper G; Ruiz-Guiñazú J; Faust SN; Spinner CD; Schuitemaker H; Van Hoof J; Douoguih M; Struyf F;
    Lancet Infect Dis; 2022 Dec; 22(12):1703-1715. PubMed ID: 36113538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
    Bennett C; Woo W; Bloch M; Cheung K; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; McCallum Pardey TG; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM;
    Lancet Infect Dis; 2024 Jun; 24(6):581-593. PubMed ID: 38460525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disparities in Influenza, Pneumococcal, COVID-19 Vaccine Coverage in High-Risk Adults Aged 19 to 64 Years in Southeastern Minnesota, 2010-2021.
    Felzer JR; Montgomery AJ; LeMahieu AM; Finney Rutten LJ; Juhn YJ; Wi CI; Jacobson RM; Kennedy CC
    Chest; 2024 Jul; 166(1):49-60. PubMed ID: 38342164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
    Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
    Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
    JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Booster vaccination using bivalent DS-5670a/b is safe and immunogenic against SARS-CoV-2 variants in children aged 5-11 years: a phase 2/3, randomized, active-controlled study.
    Suzuki R; Suda M; Ishida K; Furihata K; Ota A; Takahashi K; Sakakibara S; Nakayama T; Takeshita F
    Front Immunol; 2024; 15():1445459. PubMed ID: 39286253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.